



(11)

EP 2 790 721 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

A61K 38/08 ^(2006.01) **A61K 38/12** ^(2006.01)
A61K 38/25 ^(2006.01) **G01N 33/74** ^(2006.01)
A61P 3/04 ^(2006.01) **A61P 3/10** ^(2006.01)

(48) Corrigendum issued on:

28.11.2018 Bulletin 2018/48

(86) International application number:

PCT/IB2012/002867

(45) Date of publication and mention
of the grant of the patent:

17.10.2018 Bulletin 2018/42

(87) International publication number:

WO 2013/088241 (20.06.2013 Gazette 2013/25)

(21) Application number: **12829142.4**

(22) Date of filing: **14.12.2012**

(54) **FRAGMENTS OF UNACYLATED GHRELIN FOR USE IN THE TREATMENT OF PRADER-WILLI SYNDROME**

FRAGMENTE VON NICHT-ACYLIERTEM GHRELIN ZUR VERWENDUNG ZUR BEHANDLUNG VON PRADER-WILLI SYNDROM

FRAGMENTS DE GHRÉLINE NON ACYLÉE POUR L'UTILISATION DANS LE TRAITEMENT DU SYNDROME DE PRADER-WILLI

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(74) Representative: **Be IP**

**Cabinet LTL SAS
Centre d'Entreprise et d'Innovation
56, Bd Niels Bohr
CS 52132
69603 Villeurbanne Cedex (FR)**

(30) Priority: **15.12.2011 US 201161576217 P**

(43) Date of publication of application:

22.10.2014 Bulletin 2014/43

(56) References cited:

**EP-A1- 2 067 481 WO-A1-2005/039624
WO-A1-2008/145749 WO-A2-03/051389
US-A1- 2008 159 991 US-A1- 2011 245 160**

(73) Proprietor: **Millendo Therapeutics SAS
69130 Ecully (FR)**

(72) Inventors:

- **VAN DER LELY, Aart Jan
NL-2662 CW Bergschenhoek (NL)**
- **ABRIBAT, Thierry
F-69110 Sainte Foy Les Lyon (FR)**

- **DELPARIGI ANGELO ET AL: "High circulating ghrelin: A potential cause for hyperphagia and obesity in Prader-Willi syndrome.", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 87, no. 12, December 2002 (2002-12), pages 5461-5464, XP055061123, ISSN: 0021-972X**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 790 721 B8

- | | |
|--|---|
| <ul style="list-style-type: none">• RODRIGUEZ A ET AL: "Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes", INTERNATIONAL JOURNAL OF OBESITY, vol. 33, no. 5, May 2009 (2009-05), pages 541-552, XP002696090, ISSN: 0307-0565 | <ul style="list-style-type: none">• Anonymous: "UnAcylated Ghrelin (UAG)", Alizé Pharma , 2013, XP002696091, Retrieved from the Internet:
URL:http://www.alz-pharma.com/r-and-d-projects/unacylated-ghrelin-uag [retrieved on 2013-04-24] |
|--|---|